 |
111 Diseases |  |
5 Trials |
|
5 Trials |  |
76 News |  |
| 12» |
- | cisplatin / Generic mfg.
Enrollment closed: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Aug 30, 2024
P3, N=72, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting
- ||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Enrollment closed, Trial primary completion date: Oral Akynzeo (clinicaltrials.gov) - Apr 18, 2024
P4, N=414, Active, not recruiting, Sponsor: Helsinn Healthcare SA
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Jul 2024
- | granisetron oral / Generic mfg.
New trial: Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group (clinicaltrials.gov) - Dec 19, 2023
P=N/A, N=160, Completed, Sponsor: Ain Shams University
- | cisplatin / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Nov 18, 2023
P3, N=72, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Jul 2024 Phase classification: P=N/A --> P3 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
- || Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Trial completion date, Trial primary completion date: Oral Akynzeo (clinicaltrials.gov) - Nov 9, 2022
P4, N=530, Recruiting, Sponsor: Helsinn Healthcare SA
Phase classification: P=N/A --> P3 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2025 Trial completion date: Aug 2023 --> Nov 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- | cisplatin / Generic mfg.
Trial completion date, Trial primary completion date: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Nov 1, 2022
P=N/A, N=72, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Aug 2023 --> Nov 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
- cisplatin / Generic mfg.
5-HT3 Antagonist Antiemetic Drugs Alter Cisplatin Pharmacokinetics and Risk of Nephrotoxicity (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1095;
P=N/A
Conclusion Cisplatin-treated cancer patients prescribed ondansetron for the prevention of emesis exhibited decreased kidney function when compared to patients receiving granisetron or palonosetron. Future work will expand analyses to include additional patients, urinary excretion of cisplatin, and urinary biomarkers of kidney injury.
- Xalkori (crizotinib) / Pfizer
[VIRTUAL] Phase II Trial of Antiemetic Oral Granisetron Plus Dexamethasone for Nausea and Vomiting Caused by Crizotinib in ALK or ROS1 Fusion - Positive NSCLC (Program Auditorium) - Aug 9, 2021 - Abstract #IASLCWCLC2021IASLC_WCLC_700;
Conclusion The double combination of oral granisetron plus dexamethasone is the valid prophylactic regimen for nausea and vomiting caused by crizotinib in patients with ALK or ROS1-positive NSCLC. Clinical trial information: jRCTs031180378.
- ||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
New P4 trial: Oral Akynzeo (clinicaltrials.gov) - Mar 25, 2021
P4, N=530, Recruiting, Sponsor: Helsinn Healthcare SA
- ||| Sancuso (granisetron) / Kyowa Kirin, Solasia
Clinical, P3 data, Journal: A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. (Pubmed Central) - Dec 30, 2020
Transdermal granisetron was 82% more like to control CINV than oral ondansetron in the late phase of cycle 1 and performed similarly to oral ondansetron in all other cycles. Transdermal granisetron should be considered an option as prophylactic antiemetic therapy for gynecologic cancer survivors undergoing chemoradiation.
- | ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Biomarker, Trial completion: Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) - Mar 31, 2020
P4, N=92, Completed, Sponsor: Mayo Clinic
Transdermal granisetron should be considered an option as prophylactic antiemetic therapy for gynecologic cancer survivors undergoing chemoradiation. Recruiting --> Completed
- | cisplatin / Generic mfg.
Enrollment open, Trial primary completion date: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Sep 25, 2019
P=N/A, N=72, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2022 --> Sep 2022
- | granisetron oral / generics
Clinical, PK/PD data, Journal: Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study. (Pubmed Central) - Aug 7, 2019
The C values determined through TD and OA were equivalent, indicating similar drug exposures. Therefore, the granisetron patch may be an alternative formulation for oral granisetron in Chinese individuals..
- | ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) - Jun 3, 2019
P4, N=100, Recruiting, Sponsor: Mayo Clinic
Therefore, the granisetron patch may be an alternative formulation for oral granisetron in Chinese individuals.. Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Dec 2019
- || adavosertib (AZD1775) / AstraZeneca
Trial completion, Metastases: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (clinicaltrials.gov) - Mar 25, 2019
P1, N=33, Completed, Sponsor: AstraZeneca
Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Dec 2019 Active, not recruiting --> Completed
- | cisplatin / Generic mfg.
Trial initiation date: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Mar 22, 2019
P=N/A, N=72, Not yet recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Initiation date: Jan 2019 --> Apr 2019
- | cisplatin / Generic mfg.
New trial: Cisplatin Disposition and Kidney Injury (clinicaltrials.gov) - Jan 28, 2019
P=N/A, N=72, Not yet recruiting, Sponsor: University of Colorado, Denver
- || adavosertib (AZD1775) / AstraZeneca
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (clinicaltrials.gov) - Jan 25, 2019
P1, N=33, Active, not recruiting, Sponsor: AstraZeneca
Initiation date: Jan 2019 --> Apr 2019 Recruiting --> Active, not recruiting | N=52 --> 33 | Trial completion date: Jun 2019 --> Jan 2019 | Trial primary completion date: Jun 2019 --> Jan 2019
- | ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) - Jan 10, 2019
P4, N=100, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=52 --> 33 | Trial completion date: Jun 2019 --> Jan 2019 | Trial primary completion date: Jun 2019 --> Jan 2019 Trial completion date: Feb 2019 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Apr 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: TBE-LB2014: Tick-borne Encephalitis and Positive Borrelial Antibodies (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=100, Recruiting, Sponsor: University Medical Centre Ljubljana
Trial completion date: Feb 2019 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Apr 2019 Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020
- || adavosertib (AZD1775) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Metastases: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (clinicaltrials.gov) - Oct 2, 2018
P1, N=52, Recruiting, Sponsor: AstraZeneca
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020 N=30 --> 52 | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Jun 2019
- | ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Biomarker, New P4 trial: Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) - Apr 18, 2018
P4, N=100, Not yet recruiting, Sponsor: Mayo Clinic
- adavosertib (AZD1775) / AstraZeneca
Enrollment open, Metastases: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (clinicaltrials.gov) - Dec 20, 2017
P1, N=30, Recruiting, Sponsor: AstraZeneca
N=30 --> 52 | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- | granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Nov 17, 2017
P2, N=212, Completed, Sponsor: Assiut University
Not yet recruiting --> Recruiting Recruiting --> Completed | N=120 --> 212 | Trial primary completion date: Aug 2017 --> May 2017
- | adavosertib (AZD1775) / AstraZeneca
New P1 trial, Metastases: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer (clinicaltrials.gov) - Nov 7, 2017
P1, N=30, Not yet recruiting, Sponsor: AstraZeneca
- | olanzapine / Generic mfg.
Trial completion, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Jul 7, 2017
P3, N=401, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | N=120 --> 212 | Trial primary completion date: Aug 2017 --> May 2017 Active, not recruiting --> Completed
- | granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Jun 27, 2017
P2, N=120, Recruiting, Sponsor: Assiut University
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Aug 2017
- | Varubi (rolapitant oral) / TerSera Therap, GSK, Varubi IV (rolapitant IV) / TerSera Therap, GSK
Journal: Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. (Pubmed Central) - May 20, 2017
These results support rolapitant use as part of the antiemetic regimen in carboplatin-treated patients. Cancer 2016;122:2418-2425.
- granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Jan 26, 2017
P2, N=120, Recruiting, Sponsor: Assiut University
Cancer 2016;122:2418-2425. Trial primary completion date: Sep 2016 --> Feb 2017
- | cabazitaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: PEGAZUS: Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (clinicaltrials.gov) - Jan 24, 2017
P4, N=21, Completed, Sponsor: Sanofi
Trial primary completion date: Sep 2016 --> Feb 2017 Active, not recruiting --> Completed
- olanzapine / Generic mfg.
Trial primary completion date, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Jun 27, 2016
P3, N=372, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Apr 2015
- granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Jun 18, 2016
P2, N=120, Recruiting, Sponsor: Assiut University
Trial primary completion date: Jan 2016 --> Apr 2015 Trial primary completion date: May 2016 --> Aug 2016
- | cabazitaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases: PEGAZUS: Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (clinicaltrials.gov) - Mar 30, 2016
P4, N=21, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- | granisetron oral / Generic mfg.
Trial completion: Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers (clinicaltrials.gov) - Jan 11, 2016
P1, N=50, Completed, Sponsor: Maxinase Life Sciences Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- granisetron oral / Generic mfg.
Enrollment closed: Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers (clinicaltrials.gov) - Dec 16, 2015
P1, N=50, Active, not recruiting, Sponsor: Maxinase Life Sciences Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
New P2 trial: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Oct 28, 2015
P2, N=120, Recruiting, Sponsor: Assiut University
- granisetron oral / Generic mfg.
Enrollment open: Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers (clinicaltrials.gov) - Oct 22, 2015
P1, N=50, Recruiting, Sponsor: Maxinase Life Sciences Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- granisetron oral / Generic mfg.
New P1 trial: Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers (clinicaltrials.gov) - Sep 30, 2015
P1, N=50, Not yet recruiting, Sponsor: Maxinase Life Sciences Ltd.
- granisetron oral / Generic mfg.
Trial completion: Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles (clinicaltrials.gov) - Sep 4, 2015
P4, N=40, Completed, Sponsor: Karolinska Institutet
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | olanzapine / Generic mfg.
Enrollment closed, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Jun 16, 2015
P3, N=372, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- doxycycline / Generic mfg., granisetron oral / Generic mfg.
New trial: TBE-LB2014: Tick-borne Encephalitis and Positive Borrelial Antibodies (clinicaltrials.gov) - Jun 4, 2015
P=N/A, N=100, Recruiting, Sponsor: University Medical Centre Ljubljana
- | cabazitaxel / Generic mfg.
New P4 trial, Combination therapy, Metastases: PEGAZUS: Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (clinicaltrials.gov) - May 12, 2015
P4, N=25, Recruiting, Sponsor: Sanofi
- |||| Varubi (rolapitant oral) / TerSera Therap, GSK
Trial primary completion date, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 19, 2015
P3, N=555, Completed, Sponsor: Tesaro, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2013 --> Mar 2014
- granisetron oral / Generic mfg.
Trial primary completion date: Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles (clinicaltrials.gov) - Apr 14, 2015
P4, N=40, Active, not recruiting, Sponsor: Karolinska Institutet
Trial primary completion date: Sep 2013 --> Mar 2014 Trial primary completion date: Dec 2014 --> May 2015
- temozolomide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Compliance: Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients (clinicaltrials.gov) - Sep 22, 2014
P2, N=0, Withdrawn, Sponsor: Duke University
Trial primary completion date: Dec 2014 --> May 2015 N=90 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2016 --> Sep 2014
- granisetron oral / Generic mfg.
New P4 trial: Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles (clinicaltrials.gov) - Sep 4, 2014
P4, N=40, Active, not recruiting, Sponsor: Karolinska Institutet
- |||||| olanzapine / Generic mfg.
Enrollment open, Trial initiation date, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Aug 7, 2014
P3, N=372, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
N=90 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2016 --> Sep 2014 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014
- ||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
Trial completion, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Jul 14, 2014
P3, N=532, Completed, Sponsor: Tesaro, Inc.
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Aug 2014 Active, not recruiting --> Completed
- |||| Varubi (rolapitant oral) / TerSera Therap, GSK
Trial primary completion date, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 30, 2014
P3, N=532, Active, not recruiting, Sponsor: Tesaro, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2012 --> May 2014
- ||| Varubi (rolapitant oral) / TerSera Therap, GSK
Trial completion date, CINV: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 30, 2014
P3, N=532, Active, not recruiting, Sponsor: Tesaro, Inc.
Trial primary completion date: Dec 2012 --> May 2014 Trial completion date: Jun 2013 --> May 2014